Gossamer Bio Inc., a clinical biopharmaceutical company, has announced the approval of new stock option awards for two non-executive employees. Effective September 5, 2025, these employees will receive options to purchase a total of 87,500 shares of the company's common stock at an exercise price of $2.94 per share. The options will vest over four years, with 25% vesting after one year and the remainder vesting in equal monthly installments over the following three years. This move is part of Gossamer Bio's 2023 Employment Inducement Incentive Award Plan, aiming to recognize and reward the contributions of its team members.